LLY

1,036.37

-0.35%↓

JNJ

243.49

+0.08%↑

ABBV

232.69

+0.55%↑

NVS

166.17

+2.06%↑

MRK

121.6

+0.22%↑

LLY

1,036.37

-0.35%↓

JNJ

243.49

+0.08%↑

ABBV

232.69

+0.55%↑

NVS

166.17

+2.06%↑

MRK

121.6

+0.22%↑

LLY

1,036.37

-0.35%↓

JNJ

243.49

+0.08%↑

ABBV

232.69

+0.55%↑

NVS

166.17

+2.06%↑

MRK

121.6

+0.22%↑

LLY

1,036.37

-0.35%↓

JNJ

243.49

+0.08%↑

ABBV

232.69

+0.55%↑

NVS

166.17

+2.06%↑

MRK

121.6

+0.22%↑

LLY

1,036.37

-0.35%↓

JNJ

243.49

+0.08%↑

ABBV

232.69

+0.55%↑

NVS

166.17

+2.06%↑

MRK

121.6

+0.22%↑

Home・Akciju saraksts・Incyte Corp

Incyte Corp

Slēgts

SektorsVeselības aprūpe

101.07 0.06

Pirkt Pārdot

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

100.06

Max

103.63

Galvenie mērījumi
By Trading Economics
Ienākumi	19M 424M
Pārdošana	150M 1.4B
P/E Sektora vidējais	18.48 121.746
Peļņas marža	31.052
Darbinieki	2,617
EBITDA	-75M 507M

Rekomendācijas
By TipRanks
Rekomendācijas	Pirkt
Prognoze 12 mēnešiem	+7.94% upside

Dividendes
By Dow Jones
Nākamie ieņēmumi	2026. g. 28. apr.

Tirgus statistika
By TradingEconomics
Tirgus kapitalizācija	3.2B 21B
Iepriekšējā atvēršanas cena	101.01
Iepriekšējā slēgšanas cena	101.07

Ziņu noskaņojums

By Acuity

38%

62%

132 / 351 Rangs Healthcare

Tehniskais rādītājs

By Trading Central

Pārliecība

Bullish Evidence

59.52 / 62.66 Atbalsts un pretestība

Incyte Corp Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2026. g. 17. febr. 23:44 UTC

Karstas akcijas

Stocks to Watch: La-Z-Boy, Palo Alto Networks, Caesars

2026. g. 17. febr. 23:20 UTC

Peļņas

Palo Alto Networks Lifts FY26 Revenue Outlook as 2Q Profit Jumps -- Update

2026. g. 17. febr. 22:57 UTC

Peļņas

Santos Fiscal Year Net Profit Falls 33%, Nears Start of Alaska Project

2026. g. 17. febr. 21:59 UTC

Peļņas

Palo Alto Networks Lifts FY26 Revenue Outlook as 2Q Profit Jumps

2026. g. 17. febr. 23:54 UTC

Tirgus saruna

Nikkei May Rise as Fears About AI Disruption Ease -- Market Talk

2026. g. 17. febr. 23:54 UTC

Tirgus saruna

Global Equities Roundup: Market Talk

2026. g. 17. febr. 23:54 UTC

Tirgus saruna

Global Forex and Fixed Income Roundup: Market Talk

2026. g. 17. febr. 23:45 UTC

Tirgus saruna

Suncorp's Outperformance of IAG Could Be Hard to Sustain -- Market Talk

2026. g. 17. febr. 23:19 UTC

Peļņas

Palo Alto's Guidance Overshadows Strong Earnings. Its Stock Is Down. -- Barrons.com

2026. g. 17. febr. 23:15 UTC

Peļņas

Palo Alto's Guidance Overshadows Strong Earnings. Its Stock Is Down. -- Barrons.com

2026. g. 17. febr. 22:58 UTC

Tirgus saruna

Iegādes, apvienošanās, pārņemšana

Netflix Would Operate Warner's Studios, HBO Largely the Same -- Market Talk

2026. g. 17. febr. 22:58 UTC

Iegādes, apvienošanās, pārņemšana

BlueScope Steel: Board Committed to Optimizing Value For Shareholders

2026. g. 17. febr. 22:57 UTC

Iegādes, apvienošanās, pārņemšana

BlueScope Steel to Consider Revised SGH, Steel Dynamics Takeover Bid

2026. g. 17. febr. 22:50 UTC

Iegādes, apvienošanās, pārņemšana

Agnico-Eagle Mines Acquired 662,780 Common Shrs of Maple Gold Mines at C$2.45 Per Common Shr >AEM.T

2026. g. 17. febr. 22:44 UTC

Peļņas

Palo Alto Reports Strong Earnings. Its Stock Is Down. -- Barrons.com

2026. g. 17. febr. 22:42 UTC

Peļņas

Santos FY Net Profit Falls 33%, Nears Start of Alaska Project

2026. g. 17. febr. 22:36 UTC

Tirgus saruna

Iegādes, apvienošanās, pārņemšana

Netflix Sarandos: Paramount Causing Confusion Around Warner Deal -- Market Talk

2026. g. 17. febr. 22:36 UTC

Peļņas

Santos Final Dividend 10.3 U.S. Cents/Security

2026. g. 17. febr. 22:36 UTC

Peļņas

Santos FY Underlying Profit US$898 Million, Down 25%

2026. g. 17. febr. 22:35 UTC

Peļņas

Santos FY Revenue US$4.94 Billion, Down 8%

2026. g. 17. febr. 22:35 UTC

Peļņas

Correct: Santos FY Net Profit US$818 Million, Down 33%

2026. g. 17. febr. 22:35 UTC

Iegādes, apvienošanās, pārņemšana

Berkshire Buys New York Times Stock; Sells Apple, Bank of America, Amazon In 4Q -- Barrons.com

2026. g. 17. febr. 22:34 UTC

Peļņas

Santos FY Net Profit US$818 Billion, Down 33%

2026. g. 17. febr. 22:02 UTC

Iegādes, apvienošanās, pārņemšana

Berkshire Pares Stakes in Apple and BofA, Adds New York Times Position -- Update

2026. g. 17. febr. 21:50 UTC

Iegādes, apvienošanās, pārņemšana

Steel Dynamics: SGH Would Buy BlueScope, On-sell North American Operations to SDI, As Earlier Proposed

2026. g. 17. febr. 21:50 UTC

Tirgus saruna

Iegādes, apvienošanās, pārņemšana

Tech, Media & Telecom Roundup: Market Talk

2026. g. 17. febr. 21:50 UTC

Tirgus saruna

Basic Materials Roundup: Market Talk

2026. g. 17. febr. 21:49 UTC

Iegādes, apvienošanās, pārņemšana

Steel Dynamics Says Revised Proposal Continues to Present Highly Strategic Opportunity For SDI Shareholders

2026. g. 17. febr. 21:48 UTC

Iegādes, apvienošanās, pārņemšana

Steel Dynamics: BlueScope Offer a 56% Premium to 52-Week Volume Weighted Average Price

2026. g. 17. febr. 21:48 UTC

Iegādes, apvienošanās, pārņemšana

Steel Dynamics: Consideration To Be Comprised Entirely of Cash

Salīdzinājums

Cenas izmaiņa

Incyte Corp Prognoze

Cenas mērķis

By TipRanks

7.94% augšup

Prognoze 12 mēnešiem

Vidējais 109.13 USD 7.94%

Augstākais 135 USD

Zemākais 73 USD

Pamatojoties uz 17 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi Incyte Corp — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Pirkt

17 ratings

Pirkt

Turēt

Pārdot

Pamatojoties uz 17 analītiķiem, kas pēdējo 3 mēnešu laikā snieguši akciju vērtējumus instrumentam Incyte Corp — pēdējo 3 mēnešu laikā.

Tehniskais rādītājs

By Trading Central

59.52 / 62.66Atbalsts un pretestība

Bullish events outweigh bearish events.

All events are bearish.

Noskaņojums

By Acuity

132 / 351 Rangs Veselības aprūpe

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

Par Incyte Corp

Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for hematology/oncology, and inflammation and autoimmunity areas in the United States and internationally. The company offers JAKAFI (ruxolitinib) for treatment of intermediate or high-risk myelofibrosis, polycythemia vera, and steroid-refractory acute graft-versus-host disease; MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab) for relapsed or refractory diffuse large B-cell lymphoma; PEMAZYRE (pemigatinib), a fibroblast growth factor receptor kinase inhibitor that act as oncogenic drivers in liquid and solid tumor types; ICLUSIG (ponatinib) to treat chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia; and ZYNYZ (retifanlimab-dlwr) to treat adults with metastatic or recurrent locally advanced Merkel cell carcinoma, as well as OPZELURA cream for treatment of atopic dermatitis. Its clinical stage products include retifanlimab under Phase 3 clinical trials for squamous cell carcinoma of the anal canal and non-small cell lung cancer; axatilimab, an anti-CSF-1R monoclonal antibody under Phase 2 that is being developed as a therapy for patients with chronic GVHD; INCA033989 to inhibit oncogenesis; INCB160058, which is being developed as a disease-modifying therapeutic; and INCB99280 and INCB99318 for the treatment solid tumors. The company also develops INCB123667, INCA32459, and INCA33890, as well as Ruxolitinib cream, Povorcitinib, and INCA034460. It has collaboration out-license agreements with Novartis and Lilly; in-license agreements with Agenus, Merus, MacroGenics, and Syndax; and collaboration and license agreement with China Medical System Holdings Limited for the development and commercialization of povorcitinib. The company sells its products to specialty, retail, and hospital pharmacies, distributors, and wholesalers. The company was formerly known as Incyte Genomics Inc and changed its name to Incyte Corporation in March 2003. Incyte Corporation